Published date: Dec 31 2024

Journal Title: Journal of Ophthalmic and Vision Research

Issue title: Oct–Dec 2024, Volume 19, Issue 4

Pages: 468 – 475

DOI: 10.18502/jovr.v19i4.14578

Seyed Abolghasem Mousavi dr.sabmousavi@gmail.comNegah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Zhale Rajavirajavizhale@gmail.comNegah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Hamideh Sabbaghisabbaghi.opt@gmail.comOphthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Saeid Abdiopto.abdi@gmail.comDepartment of Optometry, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Nafeeseh Montazerinnafeeseh@mail.comNegah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Bahareh Kheiribaahaar2010@yahoo.comOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Azadeh Haseli- Monfaredkosarhaseli@gmail.comNegah Aref Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Kourosh Sheibanish_kourosh@hotmail.comBasir Eye Health Research Center, Tehran, Iran

Hemn Baghban JaldianDepartment of Optometry, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Purpose: To assess the efficiency and safety of pilocarpine eye drop 1.25% analogue (IRPilo) in comparison with its original brand-name drug (Vuity).
Methods: In this non-randomized comparative study, 75 patients with presbyopia aged 40 to 60 years were enrolled. The right eyes of these patients received either IR-Pilo (n = 45) or Vuity (n = 30) and their contralateral eyes served as controls. Refractive errors, distance best-corrected visual acuity (BCVA), near vision, amplitude of accommodation, pupil size, and intraocular pressure (IOP) were measured before and 1 to 2 hours after instillation of the eye drop.
Results: The mean refractive error was stable, except for a small myopic shift in the Vuity group. There was no significant change in distance BCVA. Near vision improved significantly in both intervention groups (P < 0.001) with preference for IR-Pilo (4 vs 2.3). Furthermore, a higher amplitude of accommodation and pupil constriction occurred after instillation of both drops, with a higher effect associated with IR-Pilo. However, IOP did not change significantly post intervention.
Conclusion: IR-Pilo and Vuity eye drops had comparable results; both were effective and led to stable distance vision and improved near vision. Both ophthalmic drugs were safe and none of them were associated with significant adverse effects.

Keywords: Accommodation, Distance Vision, Eye Drops, Near Vision, Presbyopia

1. Wolffsohn JS, Davies LN. Presbyopia: Effectiveness of correction strategies. Prog Retin Eye Res 2019;68:124–143.

2. Katz JA, Karpecki PM, Dorca A, Chiva-Razavi S, Floyd H, Barnes E, et al. Presbyopia - A review of current treatment options and emerging therapies. Clin Ophthalmol 2021;15:2167–2178.

3. Callina T, Reynolds TP. Traditional methods for the treatment of presbyopia: Spectacles, contact lenses, bifocal contact lenses [v.]. Ophthalmol Clin North Am 2006;19:25–33.

4. Grzybowski A, Markeviciute A, Zemaitiene R. A review of pharmacological presbyopia treatment. Asia Pac J Ophthalmol (Phila) 2020;9:226–233.

5. Karanfil FÇ, Turgut B. Update on presbyopia-correcting drops. Eur Ophthalmic Rev 2017;11:99–102.

6. Montés-Micó R, Charman WN. Pharmacological strategies for presbyopia correction. J Refract Surg 2019;35:803–814.

7. Orman B, Benozzi G. Overview of pharmacological treatments for presbyopia. Med Hypothesis Discov Innov Optom 2020;1:67–77.

8. Vuity - Pilocarpine ophthalmic solution for presbyopia. Med Lett Drugs Ther 2022;64:17–18.

9. Tucker T, Early J. Pilocarpine 1.25% ophthalmic solution (vuity) for the treatment of presbyopia. Am Fam Physician 2023;107:659–660.

10. Benozzi G, Perez C, Leiro J, Facal S, Orman B. Presbyopia treatment with eye drops: An eight year retrospective study. Transl Vis Sci Technol 2020;9:25.

11. Galeana CAS. Cesar A Sanchez Galeana. Pharmacologic compound to mitigate presbyopia symptoms. 2021. https://doi.org/10.21203/rs.3.rs-980227/v1

12. Benozzi G, Cortina ME, Gimeno E, Vantesone DL, Solas AE, Lorda GM, et al. A multicentric study of pharmacological treatment for presbyopia. Graefes Arch Clin Exp Ophthalmol 2021;259:2441–2450.

13. Vargas V, Vejarano F, Alió J. Pharmacological therapy for presbyopia in patients with previous corneal refractive surgery: A pilot study. Ophthalmol Ther 2020;9:1003–1010.

14. Price FW Jr, Hom M, Moshirfar M, Evans D, Liu H, Penzner J, et al. Combinations of pilocarpine and oxymetazoline for the pharmacological treatment of presbyopia: Two randomized phase 2 studies. Ophthalmol Sci 2021;1:100065.